Retension Pharmaceuticals Files 25-MB S-1/A Amendment
Retension Pharmaceuticals, Inc. filed a 25-MB S-1/A amendment with the SEC on October 5, 2026 — among the largest IPO filings of the day. The size reflects extensive clinical trial data, IP valuation disclosures, and R&D capitalization accounting.
51CFO view：A 25-MB S-1/A signals deep R&D accounting complexity: CFO must own clinical-stage expense capitalization, intangible asset amortization modeling, FDA pathway risk quantification, and SOX 404 controls over R&D spend.
Retension Pharmaceuticals, Inc. filed a 25-MB S-1/A amendment with the SEC on October 5, 2026 — among the largest IPO filings of the day. The size reflects extensive clinical trial data, IP valuation disclosures, and R&D capitalization accounting.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →